Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VictORION-Mono
2022-001109-29Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of inclisiran in hypercholesterolemia (3 arms), sponsored by Novartis. Primary endpoint: Percentage change in LDL-C from baseline to Day 150. Started Oct 2022; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2022-001109-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001109-29.